Incyte Q3 FY26: where the revenue came from and where it went
The whole income statement of Incyte for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jul 1 – Sep 30, 2026
- Reported
- Oct 29, 2026
Revenue$1.56B
+14% year over year
Gross profit$1.45B
93% margin
Operating profit−$0.71B
−45% margin
Net profit−$0.79B
−50% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 1.56 | 100% | +14% |
| Jakafi | 0.83 | 53% | +4% |
| Opzelura | 0.26 | 16% | +36% |
| Product royalty | 0.19 | 12% | +12% |
| Niktimvo | 0.07 | 4% | +47% |
| ZYNYZ | 0.06 | 4% | |
| Other | 0.06 | 4% | |
| Minjuvi/monjuvi | 0.06 | 4% | +30% |
| Milestone & contract | 0.05 | 3% | +11% |
| Cost of revenue | −0.11 | 7% | |
| Gross profit | 1.45 | 93% margin | +0pp |
| R&D | −1.79 | 115% | +78pp |
| SG&A | −0.36 | 24% | −1pp |
| Operating profit | −0.71 | −45% margin | −78pp |
| Other income, net | 0.02 | ||
| Tax | −0.10 | ||
| Net profit | −0.79 | −50% margin | −81pp |
24 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest